Table 3.

Immunohistochemistry and tumour characteristics in p53, SSTR-2a and CgA

p53	Total, rows	Negative	Het-pos.	Positive	p
	n = 162 (100%)	n = 50 (30.9%)	n = 32 (19.8%)	n = 80 (49.4%)
SSTR-2a Negative	101 (62.3%)	29 (17.9%)	12 (7.4%)	60 (37.0%)	0.01*
SSTR-2a Het-pos.	19 (11.7%)	5 (3.1%)	7 (4.3%)	7 (4.3%)
SSTR-2a Positive	42 (25.9%)	16 (9.9%)	13 (8.0%)	13 (8.0%)
NET G3, Well diff.	14 (8.6%)	6 (3.7%)	5 (3.1%)	3 (1.9%)	0.05*
NEC, Poorly diff.	148 (91.4%)	44 (27.2%)	27 (16.7%)	77 (47.5%)
Small cell	21 (13.0%)	8 (4.9%)	5 (3.1%)	8 (4.9%)	0.53
Large cell	141 (87.0%)	42 (25.9%)	27 (16.7%)	72 (44.4%)
SSTR-2a	Total, rows	Negative	Het-pos.	Positive	p
	n = 163 (100%)	n = 101 (62.0%)	n = 19 (11.7%)	n = 43 (26.4%)
CgA Negative	56 (34.4%)	45 (27.6%)	7 (4.3%)	4 (2.5%)	< 0.001*
CgA Het-pos.	40 (24.5%)	28 (17.2%)	3 (1.8%)	9 (5.5%)
CgA Positive	67 (41.1%)	28 (17.2%)	9 (5.5%)	30 (18.4%)
NET G3, Well diff.	14 (8.6%)	7 (4.3%)	0 (0%)	7 (4.3%)	0.08
NEC, Poorly diff.	149 (91.4%)	94 (57.7%)	19 (11.7%)	36 (22.1%)
Small cell	21 (12.9%)	11 (6.9%)	3 (1.8%)	7 (4.3%)	0.54
Large cell	142 (87.1%)	90 (55.2%)	16 (9.8%)	36 (22.1%)
CgA	Total, rows	Negative	Het-pos.	Positive	p
	n = 163 (100.0%)	n = 56 (34.6%)	n = 40 (24.7%)	n = 67 (40.7%)
p53 Negative	50 (30.9%)	19 (11.7%)	7 (4.3%)	24 (14.8%)	0.03*
p53 Het-pos.	32 (19.8%)	6 (3.7%)	9 (5.6%)	17 (10.5%)
p53 Positive	80 (49.4%)	31 (19.1%)	24 (14.8%)	25 (15.4%)
NET G3, Well diff.	14 (8.6%)	1 (0.6%)	3 (1.8%)	10 (6.1%)	0.03*
NEC, Poorly diff.	149 (91.4%)	55 (33.7%)	37 (22.7%)	57 (35.0%)
Small cell	21 (12.9%)	12 (7.4%)	4 (2.5%)	5 (3.1%)	0.07
Large cell	142 (87.1%)	44 (27.0%)	36 (22.1%)	62 (38.0%)

Fischer’s exact test, p-value. *Statistically significant with a p-value < 0.05